175 related articles for article (PubMed ID: 10369128)
1. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides.
Partidos CD; Salani BF; Pizza M; Rappuoli R
Immunol Lett; 1999 Apr; 67(3):209-16. PubMed ID: 10369128
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.
Erume J; Partidos CD
Afr Health Sci; 2011 Jun; 11(2):151-7. PubMed ID: 21857843
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the adjuvant effect of Escherichia coli heat-labile enterotoxin mutant (LTK63) on the systemic immune responses to intranasally co-administered measles virus nucleoprotein. Part I: antibody responses.
Erume J; Partidos H
Afr Health Sci; 2001 Aug; 1(1):3-8. PubMed ID: 12789125
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide.
Partidos CD; Pizza M; Rappuoli R; Steward MW
Immunology; 1996 Dec; 89(4):483-7. PubMed ID: 9014810
[TBL] [Abstract][Full Text] [Related]
5. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.
Neidleman JA; Vajdy M; Ugozzoli M; Ott G; O'Hagan D
Immunology; 2000 Sep; 101(1):154-60. PubMed ID: 11012767
[TBL] [Abstract][Full Text] [Related]
6. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
[TBL] [Abstract][Full Text] [Related]
7. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.
Beignon AS; Briand JP; Rappuoli R; Muller S; Partidos CD
Infect Immun; 2002 Jun; 70(6):3012-9. PubMed ID: 12010992
[TBL] [Abstract][Full Text] [Related]
8. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
[TBL] [Abstract][Full Text] [Related]
9. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
[TBL] [Abstract][Full Text] [Related]
10. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
Di Tommaso A; Saletti G; Pizza M; Rappuoli R; Dougan G; Abrignani S; Douce G; De Magistris MT
Infect Immun; 1996 Mar; 64(3):974-9. PubMed ID: 8641809
[TBL] [Abstract][Full Text] [Related]
11. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
Tierney R; Beignon AS; Rappuoli R; Muller S; Sesardic D; Partidos CD
J Infect Dis; 2003 Sep; 188(5):753-8. PubMed ID: 12934192
[TBL] [Abstract][Full Text] [Related]
12. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.
Bonenfant C; Dimier-Poisson I; Velge-Roussel F; Buzoni-Gatel D; Del Giudice G; Rappuoli R; Bout D
Infect Immun; 2001 Mar; 69(3):1605-12. PubMed ID: 11179334
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63).
Pine S; Barackman J; Ott G; O'Hagan D
J Control Release; 2002 Dec; 85(1-3):263-70. PubMed ID: 12480330
[TBL] [Abstract][Full Text] [Related]
15. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.
Ugozzoli M; Santos G; Donnelly J; O'Hagan DT
J Infect Dis; 2001 Jan; 183(2):351-354. PubMed ID: 11110644
[TBL] [Abstract][Full Text] [Related]
16. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
Nawar HF; Arce S; Russell MW; Connell TD
Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
[TBL] [Abstract][Full Text] [Related]
17. Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.
Nawar HF; Arce S; Russell MW; Connell TD
Infect Immun; 2005 Mar; 73(3):1330-42. PubMed ID: 15731030
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
[TBL] [Abstract][Full Text] [Related]
19. Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.
Smith DJ; King WF; Barnes LA; Trantolo D; Wise DL; Taubman MA
Infect Immun; 2001 Aug; 69(8):4767-73. PubMed ID: 11447149
[TBL] [Abstract][Full Text] [Related]
20. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
